Last checked at 
For the six months ended December 31, pretax loss widened to
Creo did not generate any revenue in either year. Other income, however, shrank to
"I am pleased with the progress we have made against all our strategic objectives, not only in the first half of FY 2018, but over the last twelve months," Creo Chief Executive Officer Craig Gulliford said. "Since we listed in December 2016, we have achieved CE marking and FDA clearance ahead of schedule for our first product, Speedboat RS2, in
"We are executing against our training led commercialisation plan, targeting selected clinicians and key opinion leaders to drive clinical adoption," Gulliford added. "Significantly, the first patients in the
"The advances that we have made in our pipeline positions us well to become a leading advanced energy, minimally invasive, medical device company," Gulliford continued. "We remain on track for full commercial launch in 2019."
Shares in Creo were 5.4% lower at
